Femasys Inc (FEMY)

Form 8-K - Current report

Form 8-K - Current report

Form 8-K - Current report

Femasys Expands Fertility Care Portfolio in Europe with CE Mark Approval for FemHSG™ Catheter

ATLANTA, May 13, 2026 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a leading biomedical innovator focused...

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

Femasys Announces Financial Results for Quarter Ended March 31, 2026 and Provides Corporate Update

ATLANTA, May 08, 2026 (GLOBE NEWSWIRE) --  Femasys Inc. (NASDAQ: FEMY), a leading biomedical innovator making...

Femasys Enables OB/GYNs to Deliver First-Line Fertility Treatment with Initial Commercial Use of FemaSeed® Complete

-- Integrated sperm preparation and intratubal insemination drive earlier intervention and streamlined...

Form DEF 14A - Other definitive proxy statements

Form ARS - Annual Report to Security Holders

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Femasys Launches FemaSeed® Complete for OB/GYNs at ACOG 2026

ATLANTA, April 22, 2026 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a leading biomedical innovator...

Femasys Drives International Growth with Israeli Market Entry for Fertility Portfolio

-- Partnership with AMI Technologies Positions FemaSeed® as a First-Line Infertility Treatment in Israel...

Form DEF 14A - Other definitive proxy statements

Form 4 - Statement of changes in beneficial ownership of securities